Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P950022/S150

Durata Defibrillation Leads

ABBOTT MEDICAL · Decision date Nov 20, 2025

FDA DECISIONP950022/S150

What did the FDA approve?

FDA records P950022/S150 as a supplement to PMA P950022, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Nov 20, 2025.

FDA approval order statement

approval for model line extensions for the Zenex MRI & Zenus MRI families of pacemakers and updated labeling for cardiac leads and additional pacemaker models
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Nov 20, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P950022/S150
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
APPR
Decision date
Nov 20, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

For the original device and its historical approval scope, see PMA P950022. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P950022 · Original PMA

    TVL(TM) LEAD SYSTEM

  2. P950022/S150 received

    Application receipt date recorded by FDA.

  3. P950022/S150 · FDA decision

    Normal 180 Day Track

  4. P950022/S151 · Related supplement

    Durata Leads; Optisure Leads

  5. P950022/S152 · Related supplement

    Durata Leads (7120, 7121, 7122, 7120Q, 7121Q, 7122Q, 7170, 7170Q, 7172Q, 7171Q)

  6. P950022/S154 · Related supplement

    Durata Leads; Optisure Leads; UltiSync Leads

  7. P950022/S153 · Related supplement

    UltiSynq Defibrillation lead; SurGrip Suture Sleeve Accessory

Timeline entries are records held by MedtechLedger for P950022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P950022

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA approvalMay 10, 1996FDA
ABBOTT MEDICALPMA supplementDec 9, 2025FDA
Durata, OptisureP950022/S148
ABBOTT MEDICALPMA supplementFeb 19, 2026FDA
ABBOTT MEDICALPMA supplementApr 24, 2026FDA
ABBOTT MEDICALPMA supplementJun 26, 2026FDA
ABBOTT MEDICALPMA supplementNov 5, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Medical

Headquarters
Not reported
Brand website
abbott.com
FDA applicant address
15900 Valley View Ct., Sylmar, CA, 91335

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records